Abiopharma

The company’s liability position as of March 31, 2026, by maturity dates

Dividend in the amount of 19.841 agorot per share, ex-date 5.6.26, payment 15.6.26

argenx to Host Myositis R&D Webinar on June 23, 2026

Q1 report for 2026

Quarterly report 1 for 2026

argenx to Host Myositis R&D Webinar on June 23, 2026

Communiqué de presse : Le venglustat de Sanofi a été accepté pour un examen prioritaire aux États-Unis afin de traiter la maladie de Gaucher de type 3

Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease

Dormant shares - change in the number of shares

The company’s liability position as of 31.3.26, by maturity dates